References
- Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy – rare but there!. Leuk Lymphoma 2009;50: 1083–1095.
- Thompson PA, Tam CS, Thursky K, et al. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leuk Lymphoma 2010;51:1592–1595.
- Gastroenterological Society of Australia Digestive Health Foundation. Australian and New Zealand chronic hepatitis B (CHB) recommendations [Internet]. Gastroenterological Society of Australia 2009. [Accessed 20 Mar 2013]. Available from: http://www.gesa.org.au/professional.asp?cid=26&id=51
- Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;3:531–561.
- Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–662.
- Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010;28:3199–3202.
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–185.
- Evens AM, Jovanovic BD, Su YV, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:1170–1780.
- Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92: 1839–1843.